The U.S. Centers for Disease Control and Prevention and the Food and Drug Administration said Tuesday they are recommending a “pause” in the use of the single-dose Johnson & Johnson COVID-19 vaccine out of an “abundance of caution” while an investigation is conducted into reports of apparently rare, potentially dangerous blood clots.
In a joint statement on Tuesday, the two agencies said they are “reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.”
— U.S. FDA (@US_FDA) April 13, 2021
“In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia),” said Dr. Anne Schuchat, principal deputy director of the CDC and Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research. “All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.”
“Right now, these adverse events appear to be extremely rare,” the statement added.
Johnson & Johnson did not immediately respond to an email from NPR for comment on the announcement.
More than 6.8 million doses of the Johnson & Johnson vaccine have already been administered in the U.S., alongside tens of millions of doses of vaccines produced by Pfizer-BioNTech and Moderna.
Similar concerns over rare blood clots have been raised over the Oxford-AstraZeneca vaccine, which has been widely administered in the U.K., European Union and many other countries. Last week, the European Union’s drug regulator said the benefits of the vaccine outweigh its risks.
The pause is likely to complicate the U.S. vaccination drive amid an uptick in new coronavirus infections and “vaccine hesitancy” among certain groups.
Tuesday’s statement said that the CDC would convene an advisory committee on Wednesday to “review these cases and assess their potential significance.” The FDA is also investigating the cases. The agencies said until the further review is complete, “we are recommending a pause in the use of this vaccine out of an abundance of caution.”